PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company ...

Canada-based PharmaTher has received US Food and Drug Administration (FDA) approval for its ketamine therapy for surgical ...

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, ...

The FDA has approved the racemic ketamine product known as KETARx (PharmaTher Holdings) for the treatment of post-surgical ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the ...

The latest announcement is out from PharmaTher Holdings Ltd ( ($TSE:PHRM) ). PharmaTher Holdings Ltd. has received FDA approval for its ketamine ...

The FDA has approved Ketarx, a ketamine-based drug developed by drugmaker PharmaTher, for use in pain management. The medication is now cleared by the FDA for clinical use in perioperative settings, ...

The psychedelic pharmaceutical sector continues gaining mainstream acceptance as regulatory barriers fall and medical ...

PharmaTher Holdings Ltd ( ($TSE:PHRM) ) just unveiled an update. PharmaTher Holdings Ltd. has received FDA approval for its ketamine product, ...

PharmaTher Holdings, a pre-revenue company with a CA$41.87 million market cap, is making strategic moves in the psychedelics space, focusing on ketamine-based therapies. The company is fully funded ...

(GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTC: KSIOF) (“Kneat” or the “Company”) a leader in digitizing and automating validation and quality processes, today announced financial results for the ...